BENEŠ, Petr, Tereza NEHYBOVÁ and Jan ŠMARDA. Pro- and anti-tumor effects of wedelolactone in breast cancer cells. In Natural Products in Cancer Prevention and Therapy. 2013. ISBN 978-0-9565472-2-4.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Pro- and anti-tumor effects of wedelolactone in breast cancer cells
Authors BENEŠ, Petr (203 Czech Republic, belonging to the institution), Tereza NEHYBOVÁ (203 Czech Republic, belonging to the institution) and Jan ŠMARDA (203 Czech Republic, guarantor, belonging to the institution).
Edition Natural Products in Cancer Prevention and Therapy, 2013.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 10601 Cell biology
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14310/13:00065616
Organization unit Faculty of Science
ISBN 978-0-9565472-2-4
Keywords in English breast cancer; wedelolactone; phytoestrogen; apoptosis; cell signalling
Changed by Changed by: prof. RNDr. Jan Šmarda, CSc., učo 1223. Changed: 19/2/2018 10:41.
Abstract
Natural phytocompounds and their derivatives are commonly used for prevention and treatment of various diseases, including cancer. Wedelolactone is one of the active polyphenolic compounds in extracts of Wedelia calandulaceae and Eclipta prostrata. Wedelolactone was shown to inhibit growth of breast and prostate cancer cells in vitro and in vivo. The growth inhibitory effects of wedelolactone have been largely attributed to the inhibition of IKK kinase, the key enzyme regulating the activity of NFkB. We have recently described that wedelolactone inhibits DNA synthesis and acts as catalytic inhibitor of DNA topoisomerase IIalpha. This study was designed to characterize the mechanisms of wedelolactone effects on breast cancer cells in detail. We observed that in nM concentrations, wedelolactone stimulates growth of ER-positive breast cancer cells MCF-7 and T47D by activation of genomic ER-signalling pathway. This growth-stimulatory effect was not detected in ER-negative MDA-MB-231 breast cancer cells. In uM concentrations, wedelolactone inhibits ERK but activates p53, JNK-signalling pathway and induces apoptosis of both ER-positive and ER-negative breast cancer cells. Pro-apoptotic effects of wedelolactone are enhanced by ERK inhibition but reduced by JNK and ER inhibitors. Lastly, wedelolactone-induced cytotoxicity to breast cancer cells was enhanced in hypoxic and acidic tissue culture conditions. We conclude that depending on concentration, wedelolactone can act both as tumor promoter and tumor suppressor in ER-positive breast cancer cells while only tumor suppression was detected in ER-negative cells. Interestingly, pro-apoptotic effects of wedelolactone on breast cancer cells are enhanced in specific features of tumor microenvironment.
Links
CZ.1.07/2.3.00/20.0097, interní kód MUName: IntegRECAMO: Intellectual Anchor (Acronym: IntegRECAMO)
Investor: Ministry of Education, Youth and Sports of the CR, 2.3 Human resources in research and development
NT13441, research and development projectName: Exprese proteinů rodiny Myb v adenokarcinomech tlustého střeva a vztah k jejich metastatickému potenciálu
PrintDisplayed: 5/10/2024 17:38